Common questions about Dolthene (FAQ)
Q: Is Dolthene a prescription-only medicine?
The classification of Dolthene is determined by the regulatory body in each jurisdiction and varies by the specific formulation and target species. According to official product information in some European regions, certain formulations for dogs are classified as a veterinary medicine not subject to veterinary prescription. Conversely, some bovine formulations in the U.S. are designated as Over-the-Counter (OTC) animal drugs.
Q: What is the regulatory status of Dolthene for use in humans?
Regulatory agencies like the FDA and EMA have not approved Dolthene for human use, as it is designated as a veterinary product containing Oxfendazole. The active ingredient itself is currently considered an investigational drug in human medicine. It is being studied in clinical trials for specific parasitic diseases, such as cysticercosis.
Q: Has the active ingredient in Dolthene been studied in human clinical research for any purpose?
Yes, the active ingredient Oxfendazole has been the subject of human clinical research, including Phase 1 and Phase 2 clinical trials. This research is focused on advancing its development as a potential anti-parasitic treatment. Studies have specifically examined its use for neglected tropical diseases, such as strongyloidiasis and cysticercosis.
Q: What are the warnings listed for people handling Dolthene?
Hazard statements indicate that the active substance is described as potentially damaging to fertility and the unborn child with repeated exposure. Regulatory documents require that handlers obtain special instructions, read all safety precautions, and wear protective gloves, clothing, and eye protection.
Q: Is it normal for a person to experience certain side effects after accidental contact with Dolthene?
Accidental contact with the active substance can potentially cause mechanical irritation or drying of the skin and mechanical irritation of the eyes due to the powder form. Regulatory first-aid information advises that accidental ingestion may potentially cause damage to organs (Central nervous system) if swallowed. It is important that any accidental exposure be addressed immediately as described in the product's official safety documentation.
Q: How quickly can one generally expect the described effects of Dolthene to begin?
The time it takes for the drug to begin working is related to its absorption and peak concentration time (Tmax). In target animals like cattle and sheep, this process can take a while, with peak plasma concentrations reached in 20 to 36 hours. However, human studies of the pure substance indicate it is rapidly absorbed, with peak plasma concentrations reached in about 2 hours.
Q: What is the general duration of the intended effect of a single course of Dolthene?
The intended duration of effect is indirectly suggested by the official retreatment intervals for the veterinary drug, which are typically 4 to 8 weeks apart, depending on the species and reinfection risk. The biological half-life, which measures the time for the drug concentration to reduce by half, is described as approximately 22 hours in cattle.
Q: What is the difference between Dolthene and Fenbendazole?
Dolthene contains Oxfendazole as its active ingredient, while Fenbendazole is a closely related substance. Oxfendazole is chemically the sulfoxide metabolite of Fenbendazole. This means that Fenbendazole is processed by the body and converted into the active Oxfendazole, giving it a distinct chemical structure and slightly different way the body handles the drug (pharmacokinetic profile).
Q: How does the action of Dolthene compare to similar drugs in the same class?
The active ingredient Oxfendazole is part of the Benzimidazole class of drugs. Research evaluating its properties has compared its efficacy and pharmacokinetics to some other Benzimidazoles, such as Mebendazole. These comparisons describe differences in how the drug is handled by the body.
Q: What is the difference between Oxfendazole and Mebendazole?
Both Oxfendazole and Mebendazole are part of the Benzimidazole drug class. Mebendazole is widely known as a prescription drug approved for human use to treat parasites. Oxfendazole is primarily designated for veterinary use but is being investigated in human clinical trials. Pharmacokinetic studies describe that the dose-normalized exposure of Oxfendazole was measured to be different compared to that of Mebendazole in the study context.
Q: Are there different formulations or strengths of Dolthene available?
Yes, different strengths and formulations are available, specific to the target animal species and weight. For example, the suspension for cattle has been supplied at 225 mg/mL concentration. Other suspensions, such as those formulated for dogs, may be available at a different concentration, such as 22.65 mg/mL.
Q: What are the ingredients in Dolthene besides the main active substance?
The active substance is Oxfendazole. The other components are referred to as excipients, which are inactive ingredients used in the formulation. The publicly accessible regulatory summaries and safety data sheets (SDS) do not uniformly list all excipients; the complete list of inactive ingredients can be found in the full official product label.
Q: What research evidence supports the approved uses of Dolthene?
Official efficacy claims for the approved uses are supported by adequate and well-controlled studies, including dose-confirmation and clinical field trials. Regulatory summaries of this data reported median percent efficacy of 98% or more against mature adults of all tested species at the approved dose.
Q: Are there official studies on drug resistance related to the use of Dolthene?
Yes, the study of resistance is documented as necessary in official product labeling. Regulatory documents note that a decrease in effectiveness over time, calculated by specific parasite tests, may indicate the development of resistance. The regulatory documents state that the parasite management plan may be adjusted based on the results of regular monitoring of parasite levels.
Q: What does official data say about the metabolism or clearance of the active ingredient?
Official pharmacokinetic data describes the active ingredient Oxfendazole as primarily metabolized to its sulfone derivative and the precursor fenbendazole. The drug is predominantly cleared in the feces (around 63-78% in animals) and is found to undergo negligible urinary excretion.
Q: What information is available regarding the use of Dolthene during pregnancy or lactation?
Official documentation permits use during pregnancy and lactation in cattle when administered at the specified therapeutic dose. However, there are specific regulatory constraints: the product is prohibited from use in ewes producing milk for human consumption due to residue concerns.
Q: Does Dolthene require specific monitoring of bodily functions, such as liver enzymes?
The official veterinary product label does not mandate routine monitoring of bodily functions for standard therapeutic use. However, high-dose animal studies have observed changes such as elevated clinical chemistry values and hepatocellular effects at high levels, but these are noted in the context of overdosage.
Q: Are there international differences in the approved uses for Dolthene?
Yes, official documentation describes differences in regulatory constraints related to milk-producing animals. For milk-producing cattle, use is subject to a mandatory withdrawal period in some regions (like the EU and UK), while it is prohibited from use in others (such as under US FDA regulation).
Q: Does the information mention an acceptable level of risk for Dolthene?
Yes, regulatory bodies establish an Acceptable Daily Intake (ADI) for the total residue of Oxfendazole as a key part of the formal risk assessment process. The ADI is established at 7 mu g/kg of body weight per day (Group ADI for benzimidazoles). This value is used to ensure safety margins related to food products from treated animals.
